On the stock market since 1999, it operates in the world of health and science. It has 17,900 employees. Now — the numbers.
This is an established company with proven profits.
Revenue is spread across several lines; no single product carries the company.
The gap is $1.6B. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly above the class average — a step short of the very top.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades below its recent peak — about 13% off the top. A pullback, not a collapse.
The net profit margin is 19% — still a thick cushion, though costs have been eating into it lately.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
It pays out $1.00 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales grew only 0% a year on average — the report card’s higher growth grade leans on profit power instead.
On our five-subject report card, A sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: A is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.